

**SUPPLEMENTARY TABLE 1.** Estimated vaccination coverage with selected vaccines and doses among adolescents\* aged 13–17 years by race/ethnicity† -- National Immunization Survey–Teen (NIS-Teen), United States, 2018.

Vaccines	Race/Ethnicity, % (95% CI) <sup>§</sup>										
	White only, NH (n = 11,128)	Black only, NH (n = 1,488)	Hispanic (n = 4,021)	AI/AN only, NH (n = 247)	Asian, NH (n = 601)	Multiracial, NH (n = 1,136)	Difference for Black only, NH minus White only, NH (n = 12,616)	Difference for Hispanic minus White only, NH (n = 15,149)	Difference for AI/AN only, NH minus White only, NH (n = 11,375)	Difference for Asian, NH minus White only, NH (n = 11,729)	Difference for Multiracial, NH minus White only, NH (n = 12,264)
Tdap <sup>¶</sup> ≥1 dose	89.7 ( 88.7 to 90.6)	88.4 ( 85.9 to 90.5)	87.7 ( 85.4 to 89.7)	86.4 ( 78.7 to 91.6)	87.9 ( 80.9 to 92.6)	89.0 ( 85.5 to 91.7)	-1.3 ( -3.8 to 1.2)	-2.0 ( -4.3 to 0.4)	-3.3 ( -9.7 to 3.1)	-1.8 ( -7.6 to 4.1)	-0.7 ( -3.9 to 2.5)
<b>MenACWY**</b>											
≥1 dose	86.0 ( 84.9 to 87.1)	87.1 ( 84.5 to 89.3)	87.6 ( 85.2 to 89.7)	82.6 ( 74.3 to 88.6)	85.9 ( 77.8 to 91.3)	87.1 ( 83.7 to 89.8)	1.1 ( -1.6 to 3.7)	1.6 ( -0.9 to 4.1)	-3.5 ( -10.6 to 3.7)	-0.2 ( -6.9 to 6.6)	1.0 ( -2.2 to 4.3)
≥2 doses <sup>††</sup>	48.6 ( 44.9 to 52.4)	59.2 ( 49.9 to 67.9) <sup>§§</sup>	53.4 ( 46.8 to 59.9)	34.8 ( 18.4 to 55.7)	51.0 ( 31.4 to 70.3)	43.0 ( 31.7 to 55.0)	10.6 ( 0.7 to 20.4) <sup>§§</sup>	4.8 ( -2.8 to 12.4)	-13.9 ( -33.7 to 6.0)	2.4 ( -18.5 to 23.3)	-5.7 ( -18.1 to 6.8)
<b>HPV<sup>¶¶</sup> vaccine</b>											
HPV UTD <sup>***</sup>	47.8 ( 46.2 to 49.4)	53.3 ( 49.4 to 57.2) <sup>§§</sup>	56.6 ( 53.4 to 59.8) <sup>§§</sup>	57.3 ( 47.0 to 67.0)	53.1 ( 44.7 to 61.3)	51.1 ( 45.5 to 56.6)	5.5 ( 1.2 to 9.7) <sup>§§</sup>	8.8 ( 5.2 to 12.4) <sup>§§</sup>	9.5 ( -0.8 to 19.8)	5.3 ( -3.2 to 13.9)	3.3 ( -2.5 to 9.1)
≥1 dose	63.5 ( 62.0 to 65.1)	72.8 ( 69.3 to 76.1) <sup>§§</sup>	75.5 ( 72.7 to 78.2) <sup>§§</sup>	70.1 ( 59.6 to 78.9)	65.3 ( 56.5 to 73.2)	68.0 ( 62.8 to 72.7)	9.3 ( 5.6 to 13.0) <sup>§§</sup>	12.0 ( 8.8 to 15.2) <sup>§§</sup>	6.6 ( -3.3 to 16.5)	1.8 ( -6.8 to 10.3)	4.4 ( -0.7 to 9.6)
≥2 MMR doses	92.8 ( 91.9 to 93.5)	93.1 ( 91.3 to 94.6)	89.9 ( 88.0 to 91.5) <sup>§§</sup>	91.6 ( 84.9 to 95.5)	89.0 ( 80.0 to 94.2)	92.5 ( 89.1 to 94.8)	0.4 ( -1.5 to 2.2)	-2.9 ( -4.8 to -1.0) <sup>§§</sup>	-1.2 ( -6.3 to 4.0)	-3.8 ( -10.7 to 3.1)	-0.3 ( -3.2 to 2.6)
≥3 Hepatitis B doses	93.2 ( 92.2 to 94.0)	93.1 ( 91.2 to 94.6)	89.1 ( 86.9 to 91.0) <sup>§§</sup>	92.9 ( 87.2 to 96.2)	93.3 ( 89.7 to 95.7)	92.1 ( 88.6 to 94.6)	-0.1 ( -2.0 to 1.8)	-4.1 ( -6.3 to -1.9) <sup>§§</sup>	-0.2 ( -4.7 to 4.2)	0.2 ( -3.0 to 3.3)	-1.0 ( -4.1 to 2.0)
<b>Varicella vaccine</b>											
History of varicella disease <sup>†††</sup>	11.6 ( 10.6 to 12.7)	9.2 ( 7.3 to 11.4) <sup>§§</sup>	14.2 ( 12.1 to 16.6) <sup>§§</sup>	16.1 ( 10.4 to 24.2)	12.5 ( 8.1 to 18.7)	9.4 ( 6.6 to 13.3)	-2.5 ( -4.7 to -0.2) <sup>§§</sup>	2.6 ( 0.2 to 5.0) <sup>§§</sup>	4.5 ( -2.5 to 11.5)	0.9 ( -4.5 to 6.2)	-2.2 ( -5.6 to 1.3)
No history of varicella:											
≥1 dose vaccine	95.8 ( 95.2 to 96.4)	94.2 ( 92.2 to 95.7)	93.4 ( 91.8 to 94.7) <sup>§§</sup>	94.7 ( 87.7 to 97.8)	93.3 ( 84.7 to 97.2)	95.1 ( 92.1 to 97.0)	-1.6 ( -3.5 to 0.2)	-2.4 ( -4.0 to -0.8) <sup>§§</sup>	-1.1 ( -5.8 to 3.5)	-2.5 ( -8.3 to 3.3)	-0.7 ( -3.2 to 1.7)
≥2 doses vaccine	90.8 ( 89.8 to 91.7)	89.4 ( 86.0 to 92.0)	87.6 ( 85.5 to 89.5) <sup>§§</sup>	89.9 ( 81.7 to 94.7)	86.1 ( 76.2 to 92.3)	90.3 ( 86.7 to 93.1)	-1.4 ( -4.6 to 1.7)	-3.2 ( -5.4 to -0.9) <sup>§§</sup>	-0.9 ( -7.3 to 5.4)	-4.7 ( -12.7 to 3.3)	-0.5 ( -3.7 to 2.8)
History of varicella or ≥ 2 varicella vaccine doses	91.9 ( 91.0 to 92.7)	90.3 ( 87.2 to 92.7)	89.4 ( 87.5 to 91.0) <sup>§§</sup>	91.5 ( 84.5 to 95.5)	87.8 ( 78.9 to 93.3)	91.3 ( 87.9 to 93.7)	-1.5 ( -4.4 to 1.3)	-2.5 ( -4.4 to -0.5) <sup>§§</sup>	-0.3 ( -5.7 to 5.0)	-4.0 ( -11.1 to 3.1)	-0.6 ( -3.6 to 2.4)

**Abbreviations:** AI/AN = American Indian/Alaska Native; CI = confidence interval; HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; MMR = measles, mumps, and rubella vaccine; NH = non-Hispanic; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; UTD = up-to-date.

\* Adolescents (N = 18,700) in the 2018 NIS-Teen were born January 2000 through February 2006.

† Adolescent's race/ethnicity was reported by their parent or guardian. Adolescents identified in this report as white, black, Asian, American Indian/Alaska Native or multiracial were reported by the parent or guardian as non-Hispanic. Adolescents identified as multiracial had more than one race category selected. Adolescents identified as Hispanic might be of any race. Native Hawaiian or other Pacific Islanders were not included in the table because of small sample sizes (n= 79).

§ Estimates with 95% confidence intervals > 20 may not be reliable.

¶ Includes percentages receiving Tdap vaccine at age  $\geq 10$  years.

\*\* Includes percentages receiving MenACWY and meningococcal-unknown type vaccine.

††  $\geq 2$  doses of MenACWY or meningococcal-unknown type vaccine. Calculated only among adolescents aged 17 years at interview. Does not include adolescents who received 1 dose of MenACWY vaccine at age  $\geq 16$  years.

§§ Statistically significant difference ( $p < 0.05$ ) in estimated vaccination coverage by race/ethnicity; referent group was white, non-Hispanic adolescents.

¶¶ HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV).

\*\*\* HPV UTD - Includes those with  $\geq 3$  doses, and those with 2 doses when the first HPV vaccine dose was initiated prior to age 15 years and there was at least five months minus four days between the first and second dose.

††† By parent/guardian report or provider records.